Posted by ABMN Staff on Mar 29th, 2024
B. Riley restated their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX – Free Report) in a report published on Thursday, Benzinga reports. The firm currently has a $5.00 price target on the stock.
Separately, Oppenheimer...
More of this article »